ReviewCancers2021
Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of endoscopic nasobiliary drainage versus percutaneous transhepatic cholangial drainage in the treatment of advanced hilar cholangiocarcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2024Pooled it
- Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Claudin 18.2 Expression in Cholangiocarcinoma: Clinicopathological Heterogeneity, Prognostic Significance, and Impact of Positivity Thresholds.Journal of clinical medicine · 2026Article
- The CXCL5/CXCR2 Axis Attenuates Ferroptosis in Intrahepatic Cholangiocarcinoma Through the Positive Feedback Loop Between PTGS2 Transcriptional Activation and Neutrophil Recruitment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Comparative efficacy of interventions for jaundice in hilar cholangiocarcinoma: A retrospective analysis using the Mayo staging system.Medicine · 2026Article
- Outcomes of Liver Transplant Versus Partial Hepatectomy for Perihilar Cholangiocarcinoma Patients Requiring Arterial Reconstruction.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Multiphasic Evidential Decision-Making Matrix (MedMax) for Intrahepatic Cholangiocarcinoma: A Single-Center Validation Study.Cancers · 2026Article
- Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers.Frontiers in cell and developmental biology · 2026Review
- A Multiphase CT-Based Radiomics-Clinical Model to Identify Inadequate Future Liver Remnant Hypertrophy After Portal Vein Embolization Before Major Hepatectomy.Cancer management and research · 2026Article
- Spontaneous Regression of Intrahepatic Adenocarcinoma after Needle Biopsy: A Case Report and Literature Review.Surgical case reports · 2026Article
- Prognostic value of perioperative gamma-glutamyl transferase trajectories in perihilar cholangiocarcinoma: a multicentre retrospective cohort study.Therapeutic advances in medical oncology · 2026Article
- Operative and Oncological Outcomes of Vascular Resection and Reconstruction for Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2025Article
- Regional Liver Function Assessment UsingAnnals of surgical oncology · 2025Article
- Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.Journal of liver transplantation · 2025Article
- Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database.Diseases (Basel, Switzerland) · 2025Article
- Short-term and Long-term Clinical Outcomes of Combined Caudate Lobectomy for Intrahepatic Cholangiocarcinoma Involving the Hepatic Hilus: A Propensity Score Analysis.Gut and liver · 2025Article
- Biliary metallic stent combined with radioactive 125I seeds strands for malignant hilar obstruction.BMC cancer · 2025Article
- Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.Diseases (Basel, Switzerland) · 2025Article
- Preoperative assessment of longitudinal extent in hilar cholangiocarcinoma using noninvasive enhanced MR radiomics: a multicenter study.Frontiers in oncology · 2025Article
- Preoperative Imaging Assessment and Staging of Perihilar Cholangiocarcinoma: Tips and Pitfalls.Journal of the Korean Society of Radiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma accounts for approximately 10% of all hepatobiliary tumors and represents 3% of all new-diagnosed malignancies worldwide. Intrahepatic cholangiocarcinoma (i-CCA) accounts for 10% of all cases, perihilar (h-CCA) cholangiocarcinoma represents two-thirds of the cases, while distal cholangiocarcinoma accounts for the remaining quarter. Originally described by Klatskin in 1965, h-CCA represents one of the most challenging tumors for hepatobiliary surgeons, mainly because of the anatomical vascular relationships of the biliary confluence at the hepatic hilum. Surgery is the only curative option, with the goal of a radical, margin-negative (R0) tumor resection. Continuous efforts have been made by hepatobiliary surgeons in order to achieve R0 resections, leading to the progressive development of aggressive approaches that include extended hepatectomies, associating liver partition, and portal vein ligation for staged hepatectomy, pre-operative portal vein embolization, and vascular resections. i-CCA is an aggressive biliary cancer that arises from the biliary epithelium proximal to the second-degree bile ducts. The incidence of i-CCA is dramatically increasing worldwide, and surgical resection is the only potentially curative therapy. An aggressive surgical approach, including extended liver resection and vascular reconstruction, and a greater application of systemic therapy and locoregional treatments could lead to an increase in the resection rate and the overall survival in selected i-CCA patients. Improvements achieved over the last two decades and the encouraging results recently reported have led to liver transplantation now being considered an appropriate indication for CCA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.